Cargando…
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations
OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi‐national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Me...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378691/ https://www.ncbi.nlm.nih.gov/pubmed/29802810 http://dx.doi.org/10.1111/bju.14412 |
_version_ | 1783395968098500608 |
---|---|
author | Bancroft, Elizabeth K. Saya, Sibel Page, Elizabeth C. Myhill, Kathryn Thomas, Sarah Pope, Jennifer Chamberlain, Anthony Hart, Rachel Glover, Wayne Cook, Jackie Rosario, Derek J. Helfand, Brian T. Hutten Selkirk, Christina Davidson, Rosemarie Longmuir, Mark Eccles, Diana M. Gadea, Neus Brewer, Carole Barwell, Julian Salinas, Monica Greenhalgh, Lynn Tischkowitz, Marc Henderson, Alex Evans, David Gareth Buys, Saundra S. Eeles, Rosalind A. Aaronson, Neil K. |
author_facet | Bancroft, Elizabeth K. Saya, Sibel Page, Elizabeth C. Myhill, Kathryn Thomas, Sarah Pope, Jennifer Chamberlain, Anthony Hart, Rachel Glover, Wayne Cook, Jackie Rosario, Derek J. Helfand, Brian T. Hutten Selkirk, Christina Davidson, Rosemarie Longmuir, Mark Eccles, Diana M. Gadea, Neus Brewer, Carole Barwell, Julian Salinas, Monica Greenhalgh, Lynn Tischkowitz, Marc Henderson, Alex Evans, David Gareth Buys, Saundra S. Eeles, Rosalind A. Aaronson, Neil K. |
author_sort | Bancroft, Elizabeth K. |
collection | PubMed |
description | OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi‐national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36‐item short‐form health survey (SF‐36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale‐Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants’ perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF‐36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer‐specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening. |
format | Online Article Text |
id | pubmed-6378691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63786912019-02-28 Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations Bancroft, Elizabeth K. Saya, Sibel Page, Elizabeth C. Myhill, Kathryn Thomas, Sarah Pope, Jennifer Chamberlain, Anthony Hart, Rachel Glover, Wayne Cook, Jackie Rosario, Derek J. Helfand, Brian T. Hutten Selkirk, Christina Davidson, Rosemarie Longmuir, Mark Eccles, Diana M. Gadea, Neus Brewer, Carole Barwell, Julian Salinas, Monica Greenhalgh, Lynn Tischkowitz, Marc Henderson, Alex Evans, David Gareth Buys, Saundra S. Eeles, Rosalind A. Aaronson, Neil K. BJU Int Urological Oncology OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi‐national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36‐item short‐form health survey (SF‐36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale‐Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants’ perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF‐36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer‐specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening. John Wiley and Sons Inc. 2018-06-22 2019-02 /pmc/articles/PMC6378691/ /pubmed/29802810 http://dx.doi.org/10.1111/bju.14412 Text en © 2018 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Urological Oncology Bancroft, Elizabeth K. Saya, Sibel Page, Elizabeth C. Myhill, Kathryn Thomas, Sarah Pope, Jennifer Chamberlain, Anthony Hart, Rachel Glover, Wayne Cook, Jackie Rosario, Derek J. Helfand, Brian T. Hutten Selkirk, Christina Davidson, Rosemarie Longmuir, Mark Eccles, Diana M. Gadea, Neus Brewer, Carole Barwell, Julian Salinas, Monica Greenhalgh, Lynn Tischkowitz, Marc Henderson, Alex Evans, David Gareth Buys, Saundra S. Eeles, Rosalind A. Aaronson, Neil K. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations |
title | Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations |
title_full | Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations |
title_fullStr | Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations |
title_full_unstemmed | Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations |
title_short | Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations |
title_sort | psychosocial impact of undergoing prostate cancer screening for men with brca1 or brca2 mutations |
topic | Urological Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378691/ https://www.ncbi.nlm.nih.gov/pubmed/29802810 http://dx.doi.org/10.1111/bju.14412 |
work_keys_str_mv | AT bancroftelizabethk psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT sayasibel psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT pageelizabethc psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT myhillkathryn psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT thomassarah psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT popejennifer psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT chamberlainanthony psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT hartrachel psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT gloverwayne psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT cookjackie psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT rosarioderekj psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT helfandbriant psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT huttenselkirkchristina psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT davidsonrosemarie psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT longmuirmark psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT ecclesdianam psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT gadeaneus psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT brewercarole psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT barwelljulian psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT salinasmonica psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT greenhalghlynn psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT tischkowitzmarc psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT hendersonalex psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT evansdavidgareth psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT buyssaundras psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT eelesrosalinda psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations AT aaronsonneilk psychosocialimpactofundergoingprostatecancerscreeningformenwithbrca1orbrca2mutations |